10x Genomics delivered a clean beat on profitability, though not on growth. The company lost $0.15 per share in the third quarter, well ahead of the -$0.29 consensus and the -$0.20 Earnings Whisper number, a 25.0% surprise. The loss improved 31.8% year over year. Revenue of $150.67 million topped the $147.21 million consensus by 2.3% but grew only 1.1%. Management also raised full-year revenue guidance to $625-$635 million from $610-$630 million. The central tension is that the earnings improvement comes almost entirely from cost and margin repair, while the top line is essentially flat and the instrument business is shrinking sharply. That leaves the newly shipping Atera platform to justify a stock that has already priced in a great deal of enthusiasm.
The beat deserves scrutiny, but it holds up reasonably well. Gross margin jumped to 75% from 67%. The company attributed that gain mainly to lower inventory write-downs and a better product mix, and the mix effect is partly a function of weak instrument sales. Operating expenses fell 3% to $129.0 million. R&D dropped to $52.9 million from $57.2 million, and SG&A was roughly flat despite higher litigation costs. The operating loss was halved to $16.1 million from $32.2 million. The net loss narrowed less, to $19.4 million from $27.5 million, because other expense swung to a $7.4 million charge. Stock-based compensation also declined. This is a leaner company, but the margin gains are the type that can compress again if write-downs return or instruments rebound into the mix.
The revenue breakdown is where the quarter gets interesting. Consumables rose 5% to $134.3 million, led by a 16% jump in spatial consumables to $41.2 million. That growth points to genuine utilization of the installed Visium and Xenium base. Single-cell consumables, by contrast, grew less than 1% to $93.1 million, so the franchise remains stable rather than accelerating. Instruments were the weak spot. Total instrument revenue fell 43% to $6.9 million, and spatial instruments dropped to $3.1 million from $7.1 million, even in the quarter Atera began shipping. A plausible reading is that customers paused purchases ahead of the new platform, though the release does not say so. Geographically, U.S. revenue rose 6%, while EMEA fell 7% and Asia-Pacific excluding China fell 13%. Excluding non-recurring settlement revenue, management frames 2026 growth at only 4% to 6%.
The forward story rests on two launches. Management described "extraordinary early demand" for Atera, which is now shipping globally. The company also introduced Sentira, a cloud analysis platform built on NVIDIA computing and Anthropic's Claude, which positions 10x as an AI-era data enabler. The raised guidance implies fourth-quarter revenue of roughly $172-$183 million, a substantial step up from $150.7 million. By our inference, that step-up likely depends on a meaningful Atera instrument contribution, so execution on the ramp is now the key near-term variable. The balance sheet removes any funding concern: cash and marketable securities reached $575.7 million, up from about $523 million at year-end, helped by collection of other receivables. One limitation applies to this review. The conference-call materials supplied with it describe an unrelated mining company, so they were disregarded, and this analysis relies on the press release.
The market setup is more complicated than the surprise implies. Shares opened at $45.51 after the August report and traded at $67.52 heading into this release, up 48.4% and about 64% above the 200-day moving average. The more telling move was the October 6 spike to a 52-week high of $102.81. The stock has since given back much of that gain and sits 34.3% below the peak. Investors priced in Atera euphoria and then partially unwound it. Investor sentiment improved from 0.14 to 0.22, which is more positive but still moderate. The trend readings are mixed, with price and momentum neutral while AVWAP remains negative, consistent with a stock digesting a sharp run.
The bottom line is that 10x Genomics produced a credible beat-and-raise built on margin recovery, cost discipline and healthy spatial consumables. Bears still have legitimate ammunition in 1% revenue growth, a 43% instrument decline and weakness outside the U.S. The fourth quarter now has to show that Atera's early demand converts into instrument revenue large enough to meet the implied step-up. That conversion is what the stock's round trip from $102 suggests investors have not yet fully trusted.